|
Biotecnologia Aplicada
Elfos Scientiae
ISSN: 0684-4551
Vol. 13, Num. 2, 1996
|
Biotechnologia Applicada 1996; vol 13, no 2
PRODUCTION OF RECOMBINANT ANTIBODIES IN NON-MAMMALIAN
HOSTS
Prabhakara V Choudary
Antibody Engineering Laboratory and Department of Entomology,
University of California, Davis, CA 95616, USA.
Code Number: BA96043
Sizes of Files:
Text: 5.2K
Graphics: No associated graphics files
Introduction
Antibodies are mammalian serum glycoproteins produced by B
lymphocytes of the adaptive immune system. Their principal in
vivo function is to mediate adherence of infectious agents to
phagocytes, exploiting their own two unique properties, viz.,
specificity and memory. Antibodies are classified into three
different categories, i.e., polyclonal, monoclonal or
recombinant, on the basis of the method of their production
and composition. Polyclonal antibodies are produced in rabbits
and other animals. On the other hand, monoclonal antibodies
(mAbs) are secreted by immortalized hybrid cell lines
(hybridomas). Both of these approaches use animals at some
stage of the procedure and do not allow manipulation of the
structure or function of antibodies. However, application of
the recent advances in molecular biology has made it possible
to not only eliminate our dependence on vertebrates for
antibody production but also design the structure and function
of antibodies (1). Here, I consider the suitability of
non-mammalian host systems for the production of recombinant/
engineered antibodies/ antibody fragments/ binding
molecules.
Materials and Methods
The plasmids, yeast expression vectors, AcMNPV (baculovirus)
transfer vectors, insect cell lines (Sf-9 and Sf-21) and other
(host) strains used in the studies discussed here are
commercially available. Experimental procedures have been
described earlier (1-4).
Results and Discussion
Polyclonal antibodies have found many clinical and
non-clinical applications. Polyclonal antibodies are
relatively easy and inexpensive to produce and suit most
biological and immunochemical applications. However, since
they are a mixture of antibodies invariably recognizing more
than one epitope, their application in clinical medicine have
been limited to diagnosis. Monoclonal antibodies are the
second generation antibodies that have found specialized
applications in medicine because of their origin from a single
clone. However, since large portions of their signature
sequences, viz., immunogenic regions are of murine origin,
they, similar to polyclonal antibodies, are of limited value
in immunotherapy. The recent availability of powerful genetic
engineering techniques that permit isolation and manipulation
of antibody genes has led to the development of the third
generation of antibodies, recombinant antibodies. Production
of recombinant antibodies/fragments with tailored structures
and functions started with humanization of murine mAbs,
followed by their synthesis in Escherichia coli, yeast,
bacteriophage, fungi, insect cell lines and plants (cf 1,
2).
The focus of our laboratory has been optimal production of
soluble antibodies/binding molecules of environmental health
importance in non-mammalian hosts and to engineer them to
withstand effects of special matrices such as soil and
solvents. We have cloned from murine hybridomas/ immunized
spleens genes encoding light- and Fd chains and Fab to two
different herbicides and expressed them in E. coli and
insect cell lines (3). We have also produced the light- and Fd
chains of a human antibody in insect cell lines, as evidenced
by immunoblots probed with goat anti-human Fab antibodies (T.
Nagamine and P. Choudary, unpublished). These, together with
experiments from other laboratories, pave the way not only for
producing antibodies with novel properties but also for
bypassing the use of vertebrates for antibody production (4).
Multiple applications are envisaged for the alternative hosts
expressing antibodies/ binding molecules, e.g., chimeric phage
and yeast as affinity-reactors for batch purification of
contaminated water/ soil samples and transgenic plants as
on-site bioreactors for continuous sequestering and
detoxification of pesticides and other hazardous chemicals.
Acknowledgements
Research in the author's laboratory is supported by grants
from the UC Davis Office of Research, UC Systemwide
Biotechnology Research & Education Program, Center for Water &
Wetland Resources (W-840), US EPA (CR-819047-01-0; CR 819658),
Superfund Basic Research Program (5P42 PHS ES 04699-09), NIEHS
(IP30 ES 05707), Sandia National Laboratory Livermore
(LC-9775) and California Department of Justice
(CHOUD-941900).
1. Choudary PV et al. IN: New Frontiers in Agrochemical
Immunoanalysis. D Kurtz et al. (Eds.), AOAC International,
Washington, DC 1995;pp:179-193.
2. Winter G and Milstein C.Nature 1991;349:293-299.
3. Ward VK et al. Protein Engrg. 1993; 6:981-988.
4. Lerner RA et al. Science 1992; 258:1313-1314.
Copyright 1996 Elfos Scientiae
|